New drug VV913 put to the test in healthy volunteers
NCT ID NCT07372703
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a single dose of an experimental drug called VV913 in 56 healthy Chinese men aged 18 to 45. The goal is to see if the drug is safe and how the body processes it. Participants are randomly assigned to receive either VV913 or a placebo, and no direct health benefit is expected from taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults